Nomura Asset Management Co. Ltd. Purchases 126 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Nomura Asset Management Co. Ltd. boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 0.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 54,290 shares of the medical research company’s stock after acquiring an additional 126 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in IQVIA were worth $10,669,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IQV. Vanguard Group Inc. boosted its stake in shares of IQVIA by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock valued at $3,956,087,000 after purchasing an additional 105,504 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in IQVIA by 2.5% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock valued at $481,380,000 after acquiring an additional 59,426 shares during the last quarter. Cantillon Capital Management LLC grew its holdings in IQVIA by 12.3% during the 4th quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock worth $406,018,000 after acquiring an additional 226,017 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the period. Finally, Norges Bank acquired a new position in shares of IQVIA in the 4th quarter valued at $336,041,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on IQV. Morgan Stanley upped their price objective on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Truist Financial reiterated a “buy” rating and issued a $263.00 price target (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday, March 12th. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Finally, BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $249.05.

IQVIA Price Performance

NYSE IQV opened at $177.27 on Monday. IQVIA Holdings Inc. has a 12-month low of $176.03 and a 12-month high of $253.84. The firm’s 50 day moving average is $193.15 and its 200-day moving average is $206.05. The company has a market capitalization of $31.25 billion, a PE ratio of 23.64, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.